April 28, 2012 / 12:04 PM / 6 years ago

U.S. Court rules Merck's Zetia patent valid

(Reuters) - A U.S. court on Friday ruled that the patent on Merck & Co’s (MRK.N) cholesterol fighter Zetia and a related drug Vytorin was valid and issued an injunction blocking approval of a generic version by Mylan Inc (MYL.O) until the patent expires.

A general view shows the Merck facility in Rahway, New Jersey November 28, 2005. REUTERS/Jeff Zelevansky

Mylan had admitted that its product would infringe the patent, which run until April of 2017, Merck said.

Merck earlier on Friday said first-quarter sales of Zetia, known chemically as ezetimibe, rose 6 percent to $614 million, while Vytorin, which combines Zetia with Merck’s older cholesterol drug Zocor, saw sales slip 8 percent to $444 million.

In a ruling in U.S. District court for the district of New Jersey, Judge Jose Linares declared the patent to be “valid and enforceable.”

Reporting By Bill Berkrot

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below